EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information

Laura E Marin, Daniel I Zavaleta-Guzman, Jessyca I Gutierrez-Garcia, Daniel Racoceanu, Fanny L Casado

Discover Oncology · 07.02.2025 · 16 (1)

DOI: 10.1007/s12672-025-01896-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Discover Oncology, online erschienen am 07.02.2025. Verfasst von Laura E Marin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Omics Sciences and Applied Biotechnology, Pontificia Universidad Catolica del Peru, Lima, Peru. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biopsy information and protein Prostate-Specific Antigen (PSA) levels are the most robust information available to oncologists worldwide to diagnose and decide therapies for prostate cancer patients. However, prostate cancer presents a high risk of recurrence, and the technologies used to evaluate it demand more complex resources. This paper aims to predict Biochemical Recurrence (BCR) based on Whole Slide Images (WSI) of biopsies, Gleason scores, and PSA levels. A U-net model was used to segment phenotypic features and trained on images from the Prostate Cancer Grade Assessment (PANDA) database to segment tumorous regions from pre-processed and scored WSI of biopsies. Then, the model was tested on data from publicly available repositories achieving an Intersection over Union of 87%. Tissue features, Gleason scores, and PSA levels provided high accuracy and precision in classifying patients according to their risk of presenting recurrence, for any Gleason score sampled. The trained classifier model demonstrated a 79.2% relative accuracy, and a precision of 69.7% for patients experiencing recurrences before 24 months. Our results provide a robust, cost-efficient approach using already available information to predict the risk of BCR.

Schlagwörter

Stichwörter der Autor:innen

Biochemical recurrenceGleason scoreHematoxylin and Eosin stainingProstate cancerU-Net architectureWhole slide histopathology image

Autor:innen und Institutionen

  • Institute of Omics Sciences and Applied Biotechnology, Pontificia Universidad Catolica del Peru, Lima, Peru.
  • Sorbonne University, Paris Brain Institute, CNRS, Inria, Inserm, AP-HP, Paris, France.
  • Institute of Omics Sciences and Applied Biotechnology, Pontificia Universidad Catolica del Peru, Lima, Peru. fanny.casado@pucp.edu.pe.

Zitieren

APA

Marin, L. E., Zavaleta-Guzman, D. I., Gutierrez-Garcia, J. I., Racoceanu, D., & Casado, F. L. (2025). Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information. Discover Oncology, 16(1). https://doi.org/10.1007/s12672-025-01896-7

Vancouver

Marin LE, Zavaleta-Guzman DI, Gutierrez-Garcia JI, Racoceanu D, Casado FL. Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information. Discover Oncology. 2025;16(1). doi:10.1007/s12672-025-01896-7

BibTeX
@article{Marin2025,
  author = {Marin, Laura E and Zavaleta-Guzman, Daniel I and Gutierrez-Garcia, Jessyca I and Racoceanu, Daniel and Casado, Fanny L},
  title = {Prediction of biochemical prostate cancer recurrence from any Gleason score using robust tissue structure and clinically available information},
  journal = {Discover Oncology},
  year = {2025},
  volume = {16},
  number = {1},
  doi = {10.1007/s12672-025-01896-7}
}
Kostenlos starten →